![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | C07D 471/04 | |
A61K 31/437 | |||
A61P 1/04 | |||
A61P 11/06 | |||
A61P 11/08 |
(11) | Number of the document | 1697360 |
(13) | Kind of document | T |
(96) | European patent application number | 04809082.3 |
Date of filing the European patent application | 2004-12-16 | |
(97) | Date of publication of the European application | 2006-09-06 |
(45) | Date of publication and mention of the grant of the patent | 2011-02-23 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/SE2004/001909 |
Date | 2004-12-16 |
(87) | Number | WO 2005/058895 |
Date | 2005-06-30 |
(30) | Number | Date | Country code |
0303451 | 2003-12-18 | SE |
(72) |
LILLJEQUIST, Lars, SE
LINDKVIST, Maria, SE
NORDBERG, Peter, SE
PETTERSSON, Ursula, SE
SEBHATU, Tesfai, SE
|
(73) |
AstraZeneca AB,
151 85 Södertälje,
SE
|
(54) | NOVEL CRYSTALLINE FORMS OF 2, 3 DIMETHYL-8- (2, 6-DIMETHYLBENZYLAMINO) -N-HYDROXYETHYL-IMIDAZO 1, 2-A PYRIDINE-6-CARBOXAMIDE MESYLATE SALT. |
NOVEL CRYSTALLINE FORMS OF 2, 3 DIMETHYL-8- (2, 6-DIMETHYLBENZYLAMINO) -N-HYDROXYETHYL-IMIDAZO 1, 2-A PYRIDINE-6-CARBOXAMIDE MESYLATE SALT. |